



## **ASX Release**

**23 December 2024**

### **Acrux raises \$1.34 million from Share Purchase Plan**

**Melbourne, Australia; Acrux Limited (ASX:ACR)** (the Company or Acrux) is pleased to announce it has successfully concluded its capital raising activities having raised \$1.34 million from the Share Purchase Plan ('SPP') which closed on 18 December 2024.

This follows from the recently concluded Placement to institutional and professional investors (ASX announcement 5 December 2024) bringing the total funds raised to \$4.0 million (before costs).

Funds raised by the Placement and SPP will be used to fund ongoing development programs for the Company's pipeline of topical pharmaceutical products and, in particular, to advance 4 key projects at the later stages of development at contract manufacturers prior to dossier submission to the FDA.

The Company plans to offer Placement and SPP participants one free attaching option for every share subscribed for under the Placement and SPP ('Attaching Options'). This offer will be made under a separate prospectus and is subject to shareholder approval at a general meeting. The Attaching Options intended to be quoted on the ASX will have an exercise price of 5.25 cents and expire 2 years after issuance.

Full details of the offer of the Attaching Options will be set out in the Notice of Extraordinary General Meeting and the Attaching Options prospectus to be issued in January 2025.

**This announcement has been authorised for release to the ASX by the Board of Directors.**

**For more information, please contact:**

**Michael Kotsanis**  
**CEO & Managing Director**  
E: michael.kotsanis@acrux.com.au

**Joanna Johnson**  
**CFO & Company Secretary**  
E: joanna.johnson@acrux.com.au

P: + 61 3 8379 0100

## **About Acrux**

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities.

For further information on Acrux, visit: [www.acrux.com.au](http://www.acrux.com.au)